Alemtuzumab (Lemtrada) Seen to Slow Disease Progression by Targeting Key Brain Systems
Several clinical trials have shown that alemtuzumab (Lemtrada) effectively reduces relapse rates in patients with multiple sclerosis (MS), and improves disability in the early stages of the disease. A new study adds to evidence of the drug’s efficiency by finding that it affects different aspects of disability to varying degrees, a finding…